{"id":815542,"date":"2025-02-20T08:10:01","date_gmt":"2025-02-20T13:10:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/"},"modified":"2025-02-20T08:10:01","modified_gmt":"2025-02-20T13:10:01","slug":"tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/","title":{"rendered":"TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">EDINBURGH<\/span>, Scotland\u00a0<\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Feb. 20, 2025<\/span><\/span> \/PRNewswire\/ &#8212; TC BioPharm (Holdings) PLC (&#8220;TC BioPharm&#8221; or the &#8220;Company&#8221;) (NASDAQ: TCBP)\u00a0, a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its CEO will join the Cancer Progress Panel discussion on <span class=\"xn-chron\">February 27<\/span><sup>th<\/sup> at <span class=\"xn-chron\">1:10 pm CET<\/span> at the 18th\u00a0Annual European Life Sciences CEO Forum, which will include HealthTech topics such as AI, convergence, and diagnostics.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2623481\/Bryan_Kobel.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2623481\/Bryan_Kobel.jpg\" title=\"TC BioPharm Chief Executive Officer, Bryan Kobel\" alt=\"TC BioPharm Chief Executive Officer, Bryan Kobel\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The forum will take place on the\u00a026th\u00a0&#8211; 27th\u00a0of February 2025\u00a0at the Hilton Zurich Airport Hotel. The main programme for the\u00a018th Annual ELSF will feature more than 12 hours of high-level keynotes and panel discussions.\u00a0<\/p>\n<p>Additionally, there will be a global company showcase of 50+ presentations by established public, private, emerging, and seed companies, offering innovative solutions and seeking investment and partnering opportunities. For more\u00a0information about the 18th Annual European Life Sciences CEO Forum, please <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4365938-1&amp;h=2595586763&amp;u=https%3A%2F%2Fwww.sachsforum.com%2F18elsf-about.html&amp;a=click+here\" target=\"_blank\" rel=\"nofollow\">click here<\/a>.<\/p>\n<p>\n        <b>About TC BioPharm (Holdings) PLC<\/b>\n      <\/p>\n<p>TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.<\/p>\n<p>TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II\/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line &#8211; Phase <span class=\"xn-money\">2b<\/span>\/3 pivotal trial in the treatment of acute myeloid leukemia using the Company&#8217;s proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.<\/p>\n<p>\n        <b>Forward-Looking Statements for TC BioPharm<\/b>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company&#8217;s intent or ability to affect any budget savings or execute on any M&amp;A or capital raising strategy. These statements are based on management&#8217;s current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company&#8217;s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended <span class=\"xn-chron\">December 31, 2023<\/span>, and our other reports filed with the SEC, all of which is available on the Company&#8217;s Investor Relations website at <a href=\"http:\/\/www.tcbiopharm.com\" rel=\"nofollow\">www.tcbiopharm.com<\/a> and on the SEC website at <a href=\"http:\/\/www.sec.gov\" rel=\"nofollow\">www.sec.gov<\/a>. All forward-looking statements reflect the Company&#8217;s beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.<\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CL22778&amp;sd=2025-02-20\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum-302380543.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum-302380543.html<\/a><\/p>\n<p>SOURCE  TC BioPharm<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CL22778&amp;Transmission_Id=202502200800PR_NEWS_USPR_____CL22778&amp;DateId=20250220\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire EDINBURGH, Scotland\u00a0, Feb. 20, 2025 \/PRNewswire\/ &#8212; TC BioPharm (Holdings) PLC (&#8220;TC BioPharm&#8221; or the &#8220;Company&#8221;) (NASDAQ: TCBP)\u00a0, a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its CEO will join the Cancer Progress Panel discussion on February 27th at 1:10 pm CET at the 18th\u00a0Annual European Life Sciences CEO Forum, which will include HealthTech topics such as AI, convergence, and diagnostics. The forum will take place on the\u00a026th\u00a0&#8211; 27th\u00a0of February 2025\u00a0at the Hilton Zurich Airport Hotel. The main programme for the\u00a018th Annual ELSF will feature more than 12 hours of high-level keynotes and panel discussions.\u00a0 Additionally, there will be a global company showcase of 50+ presentations by &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-815542","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire EDINBURGH, Scotland\u00a0, Feb. 20, 2025 \/PRNewswire\/ &#8212; TC BioPharm (Holdings) PLC (&#8220;TC BioPharm&#8221; or the &#8220;Company&#8221;) (NASDAQ: TCBP)\u00a0, a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its CEO will join the Cancer Progress Panel discussion on February 27th at 1:10 pm CET at the 18th\u00a0Annual European Life Sciences CEO Forum, which will include HealthTech topics such as AI, convergence, and diagnostics. The forum will take place on the\u00a026th\u00a0&#8211; 27th\u00a0of February 2025\u00a0at the Hilton Zurich Airport Hotel. The main programme for the\u00a018th Annual ELSF will feature more than 12 hours of high-level keynotes and panel discussions.\u00a0 Additionally, there will be a global company showcase of 50+ presentations by &hellip; Continue reading &quot;TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-20T13:10:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2623481\/Bryan_Kobel.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum\",\"datePublished\":\"2025-02-20T13:10:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\\\/\"},\"wordCount\":552,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2623481\\\/Bryan_Kobel.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\\\/\",\"name\":\"TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2623481\\\/Bryan_Kobel.jpg\",\"datePublished\":\"2025-02-20T13:10:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2623481\\\/Bryan_Kobel.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2623481\\\/Bryan_Kobel.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/","og_locale":"en_US","og_type":"article","og_title":"TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum - Market Newsdesk","og_description":"PR Newswire EDINBURGH, Scotland\u00a0, Feb. 20, 2025 \/PRNewswire\/ &#8212; TC BioPharm (Holdings) PLC (&#8220;TC BioPharm&#8221; or the &#8220;Company&#8221;) (NASDAQ: TCBP)\u00a0, a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its CEO will join the Cancer Progress Panel discussion on February 27th at 1:10 pm CET at the 18th\u00a0Annual European Life Sciences CEO Forum, which will include HealthTech topics such as AI, convergence, and diagnostics. The forum will take place on the\u00a026th\u00a0&#8211; 27th\u00a0of February 2025\u00a0at the Hilton Zurich Airport Hotel. The main programme for the\u00a018th Annual ELSF will feature more than 12 hours of high-level keynotes and panel discussions.\u00a0 Additionally, there will be a global company showcase of 50+ presentations by &hellip; Continue reading \"TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-20T13:10:01+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2623481\/Bryan_Kobel.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum","datePublished":"2025-02-20T13:10:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/"},"wordCount":552,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2623481\/Bryan_Kobel.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/","name":"TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2623481\/Bryan_Kobel.jpg","datePublished":"2025-02-20T13:10:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2623481\/Bryan_Kobel.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2623481\/Bryan_Kobel.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=815542"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815542\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=815542"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=815542"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=815542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}